Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.42 |
| ▸ | STK17B | O94768 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.41 |
| ▸ | PDE2A | O00408 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20421838 | 0.87 | CCND3 (0.53) | TAAR1HIF1AGPR84STK17ASTK17B | |
| SCHEMBL18493897 | 0.87 | STK17B (0.43) | MEN1NPC1RAB9AKMT2AHDAC3 | |
| SCHEMBL30395436 | 0.87 | CCND3 (0.53) | TAAR1HIF1AGPR84STK17ASTK17B | |
| SCHEMBL6267961 | 0.87 | HDAC3 (0.48) | MEN1NPC1RAB9AKMT2AHDAC3 | |
| SCHEMBL18488988 | 0.84 | JAK2 (0.56) | MEN1KMT2ATAAR1STK17ASTK17B | |
| SCHEMBL18488448 | 0.83 | HDAC3 (0.47) | HDAC3HDAC1HDAC2HDAC6TAAR1 | |
| SCHEMBL18488360 | 0.83 | APP (0.60) | NPC1RAB9AKMT2ASTK17ASTK17B | |
| SCHEMBL29555879 | 0.83 | APP (0.60) | NPC1RAB9AKMT2ASTK17ASTK17B | |
| SCHEMBL18488676 | 0.83 | TAAR1 (0.46) | MEN1NPC1RAB9AKMT2AHDAC3 | |
| SCHEMBL18488333 | 0.82 | GPR84 (0.46) | KMT2ATAAR1GPR84STK17ASTK17B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2017023899-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336734-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | MEN1 2897/4885NPC1 4216/4885RAB9A 1307/4885 |
| US-20180215738-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | MEN1 2897/4885NPC1 4216/4885RAB9A 1307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.